Procept Biorobotics Corp (PRCT) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Procept Biorobotics Corp stock $5.41, price $20.62, that is 73.8% below the price, quality 45 out of 100. Rating: strongly overvalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 5, 2026.
How to read this chart
60‑month range $16.69 – $99.45 · fair‑value band $3.57 – $6.77 · the $20.62 price screens above the $5.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 5, 2026.
Follow Procept Biorobotics in your weekly email
Every Wednesday you see whether Procept Biorobotics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally.
Show moreShow less
It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia.
The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia.
PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Stock analysis
Procept Biorobotics Corp (PRCT) currently trades at $20.62, while our model-based Fair Value estimate is $5.41, 74% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $3.57 (bear) to $6.77 (bull), the price of $20.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Procept Biorobotics Corp reported revenue of $308M in FY2025 versus $34.5M in FY2021, a compound +72.9%/yr. Reported net income was −$95.6M in FY2025.
Key figures
Market cap $1.2B Small · P/S ratio 3.65 · EPS (TTM) $−1.94 · Net margin −32.5% · Return on equity −30.2% · Return on assets (EBIT) −21.5% (5-year average) · Operating margin −32.1% · Revenue (TTM) $337M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).
What moves the price
The share trades about 43% below its 52-week high and 24% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −15% fair-value upside, at −74%, PRCT screens richer than that median.
Fair Value models
Bear$3.57Fair Value $5.41Bull$6.77
Price $20.62 · Downside -73.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
In the last 6 months, one officer or director bought shares worth $498,315, on Aug 7, 2026. Over the same period, 4 people sold shares worth $143,184.
SalePooja SharmaChief Strat/Marketing Officer4,710 shares at $19.71$92,853Nov 6, 2026
SaleBarry L TemplinEVP, Chief Technology Officer2× since Jun 8, 2026: 731 shares, avg. $24.64$18,010Sep 9, 2026
SaleAlaleh NouriEVP, CLO, CORP. SEC.6× since Mar 6, 2026: 16,384 shares, avg. $24.94$408,665Sep 9, 2026
SaleKevin WatersEVP, CFO4× since Mar 6, 2026: 8,157 shares, avg. $24.17$197,143Sep 9, 2026
BuyLarry L WoodPresident, CEO, Director23,900 shares at $20.85$498,315Aug 7, 2026
BuyAntal Rohit DesaiDirector426,262 shares at $24.59$10.5MMar 9, 2026
Plus 13 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+37.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+60.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+109.0%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+91.9%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−619.4% (2020) → −33.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
News mood ⓘNews mood, the average tone of recent news (92 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Positive
Recent news coverage is more positive than average.
Compare Procept Biorobotics Corp with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score45 · Below median
Fair Value upside−73.8% · Bottom 25%
Profitability
Return on assets−18.8% · Bottom 25%
Net margin (12 months)−32.5% · Bottom 25%
Operating margin (12 months)−32.1% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)19.3% · Above median
Balance sheet
Debt / equity0.14× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B3.18× · Pricier than median
P/S (12 months)3.45× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)97· sector 36
PAST (return on equity)0· sector 17
HEALTH (low debt)93· sector 98
DIVIDEND (yield)0· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Procept Biorobotics Corp (PRCT) overvalued or undervalued?
As of Nov 5, 2026, our model estimates a fair value of $5.41 versus a price of $20.62, about 74% lower (overvalued).
What is the fair value of PRCT?
Our model-based fair value for Procept Biorobotics Corp is $5.41 (as of Nov 5, 2026), built from audited fundamentals. The current price: $20.62.
What is the quality score of PRCT?
Procept Biorobotics Corp has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Procept Biorobotics Corp (PRCT)?
Our model-based price target is the fair value of $5.41 (as of Nov 5, 2026) from 1 valuation models. Cautious scenario $3.57, optimistic scenario $6.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Procept Biorobotics Corp stock forecast for 2026?
Our models put fair value at $5.41, about 74% lower versus a price of $20.62 (overvalued). Cautious scenario $3.57, optimistic scenario $6.77. The calculation is refreshed regularly with new filings.
What is the revenue of Procept Biorobotics Corp (PRCT)?
Procept Biorobotics Corp reported trailing-twelve-month revenue of about $337M (latest available figure, as of Nov 5, 2026).
What is the intrinsic value of Procept Biorobotics Corp (PRCT)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Procept Biorobotics Corp it is $5.41 per share (as of Nov 5, 2026), against a price of $20.62. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Procept Biorobotics Corp stock overvalued or undervalued in 2026?
As of Nov 5, 2026, PRCT trades above its calculated fair value: price $20.62, fair value $5.41, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PRCT?
No. The price is what the market pays today ($20.62); the fair value is what the company's own numbers justify ($5.41). For Procept Biorobotics Corp the two are $15.21 per share apart. That gap is exactly why we show both numbers side by side.
How much is Procept Biorobotics Corp worth?
The market values Procept Biorobotics Corp at about $1.2B (market capitalisation, as of Nov 5, 2026). Per share that is $20.62; our models calculate a fair value of $5.41 per share.
What do the bullish and bearish scenarios say about PRCT?
Our models span a range for Procept Biorobotics Corp: cautious scenario $3.57, base $5.41, optimistic $6.77 per share (as of Nov 5, 2026, price $20.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Procept Biorobotics Corp (PRCT)?
Balance-sheet figures for Procept Biorobotics Corp (as of Nov 5, 2026): return on equity −30.2%, debt of 0.14 per unit of equity. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is PRCT from its 52-week high?
Procept Biorobotics Corp trades at $20.62, about 43% below its 52-week high of $36.10 and 24% above the low of $16.69 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of $5.41 is for.
Which stocks are comparable to Procept Biorobotics Corp?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Procept Biorobotics Corp stock attractive at the current price?
The data as of Nov 5, 2026: price $20.62, calculated fair value $5.41 (−74%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PRCT calculated?
We run Procept Biorobotics Corp through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $5.41 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Procept Biorobotics Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Procept Biorobotics Corp (PRCT)?
The closing price on Nov 6, 2026 was $20.62. Our model-based fair value is $5.41, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Procept Biorobotics Corp right now?
The price sits above even our optimistic bull case ($6.77). The favourable scenario is already priced in. Weak quality (45/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($3.57 to $6.77) leaves room in how you read the outcome.
Key figures of Procept Biorobotics Corp
How large is the market capitalisation of Procept Biorobotics Corp (PRCT)?
The market capitalisation of Procept Biorobotics Corp is $1.2B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Procept Biorobotics Corp (PRCT)?
The price-to-sales ratio of Procept Biorobotics Corp is 3.65 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Procept Biorobotics Corp (PRCT)?
Earnings per share at Procept Biorobotics Corp are $−1.94. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Procept Biorobotics Corp (PRCT)?
The net margin of Procept Biorobotics Corp is −32.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Procept Biorobotics Corp (PRCT)?
The return on equity (ROE) of Procept Biorobotics Corp is −30.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Procept Biorobotics Corp (PRCT)?
On an EBIT basis the return on assets of Procept Biorobotics Corp is −21.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Procept Biorobotics Corp (PRCT)?
The operating margin of Procept Biorobotics Corp is −32.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Procept Biorobotics Corp (PRCT)?
Revenue at Procept Biorobotics Corp is growing +19.3% versus a year earlier (3y avg +60.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Procept Biorobotics Corp (PRCT) generate?
The free cash flow of Procept Biorobotics Corp is −$58.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Procept Biorobotics Corp (PRCT) hold?
Procept Biorobotics Corp holds more cash than debt, $235M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Procept Biorobotics Corp in the live analysis
One click puts Procept Biorobotics Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 5, 2026
